The Randomized Elimination or ProLongation of Angiotensin Converting Enzyme inhibitors and angiotensin receptor blockers in Coronavirus Disease 2019
This trial is open to hospitalized patients only.
Doctors have noticed that patients with high blood pressure, diabetes, or heart disease have a
higher risk of death from COVID-19. We want to better understand why this happens and how
to treat it so we can help patients with COVID-19 get better.
The purpose of the study is to
compare the effect of stopping versus continuing ACEI or ARBs in patients who have COVID-19.
You have been invited to participate in this research study because the treating team suspects
you have developed COVID-19, or you have tested positive for it, and you regularly take either
an ACEI or ARB as part of your clinical care.
ACEI and ARBs may impact how COVID-19 affects the body, but we do not know if these
medications help or hurt the virus. These medications may enhance binding of the virus to cells
in the body (which would be harmful), but they may also enhance the protective response of
the body to the virus (which would be helpful). Since we don’t know whether these can ben
benefitial or harmful, our goal is to look at the effect of temporarily stopping these medications
while someone is hospitalized for COVID-19.